Core Viewpoint - The legal opinion letter from Hunan Qiyuan Law Firm confirms that Shengxiang Biotechnology Co., Ltd. is eligible to implement its 2025 restricted stock incentive plan, having complied with relevant laws and regulations [1][2][6]. Group 1: Company Background - Shengxiang Biotechnology was established by the transformation of Hunan Shengxiang Biotechnology Co., Ltd. and was officially registered on August 30, 2019 [4]. - The company received approval from the China Securities Regulatory Commission for its initial public offering, issuing 40 million shares on August 8, 2020, and is listed on the Shanghai Stock Exchange under the stock code 688289 [4]. Group 2: Legal Compliance - The law firm has verified that the company meets all legal requirements to proceed with the incentive plan, including the absence of any conditions that would necessitate termination or suspension of the plan [6][10]. - The firm has confirmed that the company has provided all necessary documentation and that there are no significant omissions or misrepresentations [2][3]. Group 3: Incentive Plan Details - The 2025 restricted stock incentive plan was approved by the company's board on July 10, 2025, and includes provisions for the purpose, management, and distribution of rights among the incentive recipients [7][10]. - The plan specifies that the funding for the incentive will come from the participants' own resources, with the company not providing any financial assistance [12]. Group 4: Impact on Stakeholders - The board's remuneration and assessment committee has indicated that the incentive plan is beneficial for the company's sustainable development and does not harm the interests of the company or its shareholders [12][13]. - The incentive plan's implementation is contingent upon further legal procedures and approval from the shareholders' meeting [9][14].

Core Viewpoint - The report serves as an independent financial advisory opinion on the 2025 Restricted Stock Incentive Plan of Shengxiang Biotechnology Co., Ltd, ensuring compliance with relevant laws and regulations while assessing the plan's feasibility and potential impact on the company's sustainable development and shareholder interests [1][2][18]. Group 1: Independent Financial Advisor's Role - The independent financial advisor, Shanghai Miaodao Enterprise Management Consulting Co., Ltd, was commissioned to provide an advisory report based on the 2025 Restricted Stock Incentive Plan [1]. - The advisor conducted due diligence and confirmed that the professional opinions expressed align with the disclosed documents of the company [2][3]. Group 2: Incentive Plan Overview - The incentive plan involves granting 1,192,600 restricted stocks, accounting for approximately 0.21% of the company's total share capital of 579,388,006 shares [5][6]. - The plan is designed to motivate key employees of the wholly-owned subsidiary, Zhongshan Shengxiang Haiji Biotechnology Co., Ltd, and is structured to align the interests of the company, shareholders, and core team members [23]. Group 3: Conditions and Terms - The grant price for the restricted stocks is set at 16.40 RMB per share, which is 79.46% of the average trading price on the day before the plan was announced [10][11]. - The plan includes specific performance targets for the subsidiary, with net profit goals of no less than 140 million RMB for 2025 and 180 million RMB for 2026 [12][16]. Group 4: Compliance and Feasibility - The plan complies with the relevant regulations, including the Management Measures and the Self-Regulatory Guidelines, ensuring that the granting conditions and procedures are legally sound [18][19]. - The independent financial advisor confirmed that the plan's implementation would positively impact the company's sustainable operations and shareholder equity [23][24]. Group 5: Performance Evaluation - The performance evaluation system for the incentive plan includes both company-level and individual-level assessments, ensuring a comprehensive evaluation of the employees' contributions [26]. - The plan's structure is designed to motivate employees while ensuring that the interests of shareholders are not compromised [25][26].

Core Viewpoint - The legal opinion from Beijing Jincheng Tongda (Shenyang) Law Firm confirms that the price adjustment for Yantai Ruichuang Micro-Nano Technology Co., Ltd.'s stock incentive plan has received necessary approvals and complies with relevant laws and regulations [1][11]. Summary by Sections Price Adjustment Approval and Authorization - The board of directors and the supervisory board of Yantai Ruichuang Micro-Nano Technology Co., Ltd. have approved the stock incentive plan and its related matters, ensuring no harm to the interests of the company and its shareholders [2][4]. Price Adjustment Details - The adjustment of the stock incentive plan's grant price is due to the company's capital actions, such as cash dividends, which necessitate a recalibration of the grant price [11]. - The new grant price is calculated as follows: P = P0 - V, where P0 is the original grant price, and V is the cash dividend per share. The adjusted price is 19.635 yuan per share after accounting for a cash dividend of 0.08 yuan [12]. Compliance and Conclusion - The legal opinion asserts that the price adjustment has been properly authorized and aligns with the provisions of the relevant laws, including the Company Law and Securities Law, as well as the company's articles of association [11][12].

(产品代码: 588800) ★ 跟踪：上证科创板100指数 烟台睿创微纳技术股份有限公司监事会 关于 2025 年限制性股票激励计划授予激励对象名单的核查 意见（截至授予日） 烟台睿创微纳技术股份有限公司（以下简称"公司"或"睿创微纳"）监事 会依据《中华人民共和国公司法》 （以下简称"《公司法》"）、 《中华人民共和国证 券法》 （以下简称"《证券法》"）、 《上市公司股权激励管理办法》 （以下简称"《管 理办法》"）、 《上海证券交易所科创板股票上市规则》 （以下简称"《上市规则》"）、 《科创板上市公司自律监管指南第 4 号——股权激励信息披露》等相关法律、法 规及规范性文件和《烟台睿创微纳技术股份有限公司章程》 （以下简称"《公司章 程》"）的有关规定，对公司 2025 年限制性股票激励计划（以下简称"本次激励 计划"）授予激励对象名单（截至授予日）进行了核查，发表核查意见如下： 激励对象的下列情形： （1）最近 12 个月内被证券交易所认定为不适当人选； （2）最近 12 个月内被中国证监会及其派出机构认定为不适当人选； （3）最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政处 罚 ...

Core Viewpoint - The stock of Everbright Jiabao Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days from July 9 to July 11, 2025, which is classified as an abnormal trading situation according to the Shanghai Stock Exchange rules [1][4][6]. Financial Performance - For the fiscal year 2024, the company reported a revenue of CNY 1,817,734,805.35, a decrease of 58.59% compared to the previous year. The net profit attributable to shareholders was -CNY 1,394,338,884.70, and the net profit after deducting non-recurring gains and losses was -CNY 1,511,103,796.23 [2][6]. - In the first quarter of 2025, the company achieved a revenue of CNY 310,713,649.40, down 9.05% year-on-year, with a net profit of -CNY 118,220,254.22 and a net profit after deducting non-recurring gains and losses of -CNY 124,695,272.81 [2][6]. Shareholder Actions - The company disclosed a share reduction plan by its major shareholders, Shanghai Jiading Jianye Investment Development Co., Ltd. and its concerted party, Shanghai Jiading Technology Investment (Group) Co., Ltd., intending to reduce their holdings by up to 14,996,854 shares, not exceeding 1% of the total share capital, within three months after the announcement [3][6]. Market Position - As of July 11, 2025, the company's price-to-book ratio was 1.62, which is higher than the industry average of 0.82 for the "K70 Real Estate" sector [2][5][6]. Operational Status - The company confirmed that its production and operational order remains normal, with no significant changes in the internal and external operating environment [4][5].

本激励计划的有效期为自股票期权授权日起至激励对象获授的股票期权全部行权或注销完毕之日止，最 长不超过48个月。 本激励计划授予股票期权的行权价格为27.08元/份。 本激励计划涉及的授予激励对象共计44人，包括公司公告本激励计划时在公司(含分公司和控股子公司) 任职的核心业务、核心技术人员，不含奥尼电子独立董事、监事、单独或合计持有公司5%以上股份的 股东或实际控制人及其配偶、父母、子女以及外籍员工。 格隆汇7月11日丨奥尼电子(301189.SZ)公布2025年股票期权激励计划(草案)，本激励计划拟授予激励对 象的股票期权数量为200.00万份，约占本激励计划草案公布日公司股本总额11,639.6465万股的1.72%。 本次授予为一次性授予，无预留权益。本激励计划下授予的每份股票期权拥有在满足生效条件和生效安 排的情况下，在可行权期内以行权价格购买1股本公司人民币A股普通股股票的权利。 公司2025年限制性股票激励计划所涉及的标的股票数量为300.00万股，其中，第一类限制性股票数量为 150.00万股，第二类限制性股票数量为150.00万股。本激励计划所涉及的标的股票数量为200.00万股， 因此公司全 ...

Core Viewpoint - The Shenzhen Stock Exchange announced a revision to the ChiNext Composite Index, set to be implemented on July 25, 2025, which aims to enhance the index's investment quality and attract long-term capital inflow [1][2]. Group 1: Index Revision Details - The revision introduces a monthly removal mechanism for stocks under risk warning (ST or *ST) and an ESG negative screening mechanism for stocks rated C or below, which is expected to improve the quality of sample stocks without altering the index's positioning [2][3]. - The ChiNext Composite Index has been operational since August 2010, reflecting the overall performance of all stocks listed on the ChiNext, characterized by balanced industry distribution and strong growth potential [2][4]. Group 2: Fund Company Responses - Several fund companies, including Penghua Fund and Bosera Fund, have quickly submitted applications for ChiNext Composite Index-related ETFs, indicating strong recognition of the index's long-term investment value [1][5]. - Fund managers highlighted that the index's comprehensive coverage allows it to reflect the overall market trends, benefiting both large and small growth companies, and facilitating the inclusion of potential "unicorn" companies [4][5]. Group 3: Investment Opportunities - The ChiNext Composite Index is seen as a vital tool for investors to participate in China's economic transformation, with its three unique advantages: balanced industry distribution, a complete growth ladder, and superior historical performance compared to the ChiNext Index [5][6]. - The introduction of enhanced ETFs is expected to improve liquidity in the sector and uncover potential stocks, providing investors with innovative investment tools [6].

| 上海市锦天城（深圳）律师事务所 | | | | | | --- | --- | --- | --- | --- | | 关于深圳爱克莱特科技股份有限公司 | | | | | | 法律意见书 | | | | | | 地址：深圳市福田中心区福华三路卓越世纪中心 | 1 | 号楼 21/22/23 | 层 | | | 电话：0755-82816698 | 传真：0755-82816898 | | | | | 上海市锦天城（深圳）律师事务 | | | | | | 所 | | | | 法律意见书 | | | 目 | 录 | | | | 上海市锦天城（深圳）律师事务所 | | | 法律意见书 | | | 释 义 | | | | | | 本法律意见书中，除非文义另有所指，下述词语分别具有以下含义： | | | | | | 公司、爱克股份 指 深圳爱克莱特科技股份有限公司 | | | | | | 激励计划、本次激励 | | | | | | 指 | 深圳爱克莱特科技股份有限公司2025年限制性股票激励计划 | | | | | 计划、本激励计划 | | | | | | 《激励计划（草 | | 《深圳爱克莱特科技股份有限公司2 ...

证券代码：688543 证券简称：国科军工 公告编号：2025-041 江西国科军工集团股份有限公司 关于调整 2024 年限制性股票 激励计划授予价格及数量的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江西国科军工集团股份有限公司（以下简称"公司"）于 2025 年 7 月 11 日 召开第三届董事会第十八次会议，审议通过了《关于调整 2024 年限制性股票激 励计划授予价格及数量的议案》，同意公司 2024 年限制性股票激励计划股票授 予价格由 21.13 元/股调整为 16.89 元/股，授予限制性股票数量由 360.0000 万股 调整为 431.3160 万股。现将相关事项公告如下： 一、限制性股票激励计划已履行的决策程序 了《关于公司 2024 年限制性股票激励计划（草案）及其摘要的议案》《关于制 定公司<2024 年限制性股票激励计划实施考核管理办法>的议案》以及《关于提 请公司股东大会授权董事会办理公司 2024 年限制性股票激励计划相关事宜的议 案》等议案。 同日，公司召开第三届监事会第八次会议， ...

证券代码：300782 证券简称：卓胜微 公告编号：2025-062 江苏卓胜微电子股份有限公司 关于 2023 年限制性股票激励计划第二个归属期第二批次 归属结果暨股份上市的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 重要内容提示： 制性股票不设限售期。 江苏卓胜微电子股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召 开第三届董事会第十一次会议、第三届监事会第十一次会议，审议通过了《关于 公司 2023 年限制性股票激励计划第二个归属期归属条件成就的议案》。 近日，公司办理了 2023 年限制性股票激励计划第二个归属期第二批次归属 股份的登记工作，现将有关事项说明如下： 一、 本次激励计划简述及已履行的相关审批程序 （一）2023 年限制性股票激励计划简述 司<2023 年限制性股票激励计划（草案）>及其摘要的议案》等相关议案。公司 激励计划主要内容如下： 本激励计划采用的激励工具为第二类限制性股票，涉及的标的股票来源为公 司向激励对象定向发行公司 A 股普通股股票。 本激励计划拟授予的限制性股票总量为 193.7670 万股 ...